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ABSTRACT 
The prognosis of chromosome 17 (chr17) abnormalities in patients with primary 
myelodysplastic syndrome (MDS) remains unclear. The revised International 
Prognostic Scoring System (IPSS-R) includes these abnormalities within the 
intermediate cytogenetic risk group.  
This study assessed the impact on overall survival (OS) and risk of acute 
myeloid leukemia transformation (AMLt) of chr17 abnormalities in 88 patients 
with primary MDS. We have compared this group with 1,346 patients with 
primary MDS and abnormal karyotype without chr17 involved. 
Chr17 abnormalities should be considered in the high-risk cytogenetic category. 
Monosomy 17 should be included within very-poor prognosis and i(17q), as no-
complex karyotype should be continued within the intermediate-risk group. 
INTRODUCTION 
 
Myelodysplastic syndromes (MDS) are a heterogeneous group of clonal 
hematopoietic stem cell disorders (ref. 1-3). The prognosis and clinical course 
of MDS is highly variable and several scoring systems have been developed to 
assess the prognosis (ref. 4-7). The International Prognostic Scoring System 
(IPSS) has become the gold standard for risk assessment in patients with de 
novo MDS (ref. 4).  However, one of the main pitfalls of this scoring system is 
that it includes different chromosomal aberrations without knowing the 
prognostic implications. Abnormalities of chromosome 17 (chr17) occurs in 2% 
of patients with de novo MDS and belong to the intermediate cytogenetic risk 
group according to the IPSS. The prognosis of chr17 abnormalities in patients 
with primary MDS remains unclear with great discrepancies between published 
studies (ref. 8-21). A recent study about prognostic value of i(17q) in MDS gives 
it in the intermediate prognostic group (ref. 22). The aims of this work are to 
assess the characteristics of a series of 88 patients with de novo MDS and 
chr17 abnormalities, to analyze the prognostic value of different chromosome 
17 aberrations, and to study their prognostic impact compared to 1,346 patients 
with primary MDS and an abnormal karyotype but without abnormalities of 
chr17.  
  
MATERIAL AND METHODS 
Data Collection 
The Spanish Registry of MDS is a database of the Spanish cooperative group 
on MDS.  This database includes retrospective and prospective clinical and 
biological data from patients diagnosed of MDS at the participating institutions.  
 
Patients and diagnostic criteria 
A study group of 88 patients with primary MDS and an abnormality of chr17 
along with a control group of 1,346 patients with primary MDS and an abnormal 
karyotype but without abnormalities of chr17 included in the database of the 
Spanish Registry of MDS constitute the population of the present report.  The 
diagnosis of MDS was made according to WHO 2001 criteria (ref. 2).  The 
following work is a retrospective study. We did not a specific study of the 
anomalies of the chr17 for lack of sufficient morphological data. However, 
several studies showed that some alterations of the chr17 are associated with 
the presence of hypercellularity, pseudo–Pelger–Huët, cells containing small 
vacuoles, prominent basophilia and eosinophilia, and marked increase of 
micromegakaryocytes (ref. 13-16). 
In all patients included in this study, cytogenetic abnormalities have been 
detected by conventional cytogenetic procedure. The criteria defined by the 
International System for Human Cytogenetic Nomenclature in 2009 were used 
for identification of abnormal clones (ref. 23-24). 
In keeping with the guidelines of the Declaration of Helsinki, this retrospective 
non-interventional study was conducted with the approval of the internal review 
board from the participating institutions belonging to Spanish Registry of MDS. 
 
Prognostic factors 
The main prognostic factors evaluated for OS and AML transformation, 
recorded at the time of diagnosis, are summarized in Table 1. Classification 
systems included WHO 2001 (ref. 2) and IPSS scoring system (ref. 4).  
 
Statistical analysis 
Comparisons of proportions and ranges of variables between different groups 
were performed by Chi-square, Fisher, Student’s t-test, Mann-Whitney U-test or 
One-Way ANOVA as appropriate.  
The Kaplan-Meier product limit method was used to estimate the probability of 
OS and risk of AML transformation, OS was measured from hematological 
diagnosis to death or last follow-up. All deaths, whether related or not to MDS, 
were considered as the endpoint of the follow-up interval.  AML transformation 
was measured from diagnosis to AML development. Patients dying from any 
cause before developing AML were considered as censored data in the date of 
death for the calculation of AML transformation curves. Statistical comparisons 
between different actuarial curves were based on log-rank tests. 
Multivariate analysis using the Cox proportional hazards regression method for 
temporal events was used to identify the most significant independent 
prognostic variables for OS and AML transformation. 
The selected p value for considering differences as statistically significant in all 
analyses was p<0.05. All analyses were performed using the statistical package 
PASW version 18.0 (IBM Corporation, Armonk, NY. USA). 
 
 
RESULTS 
 
Characteristics of the patients with abnormality of chr17 
The main characteristics of the patients at the time of diagnosis are summarized 
in Table 1. The series included 57 males (64.8%) and 31 females (35.2%) with 
a median age of 71.8 years (range: 23–92 years). The median value for 
hemoglobin level, ANC and platelet count was 9.0 g/dL, 1.97 x 109 per liter and 
112 x 109 per liter, respectively, whereas median BM blast count was 7.1%. 
Most of the patients were classified as RAEB (69.3%) or RA (23.9%) according 
to the FAB classification; and RAEB-1 (28.6%) or RAEB-2 (44.0%) by WHO 
criteria. The IPSS risk group was intermediate-1 in 19 patients (22.1%), 
intermediate-2 in 35 patients (40.7%) and high risk in 32 patients (37.2%).  
In total, 72 patients (81.8%) had a loss of short arm of chr17 and 16 patients 
(18.2%) did not have this loss.  
In relation to karyotype complexity, 18 patients (20.5%) had an abnormal chr17 
as isolated chromosomal abnormality, 8 (9.1%) had one additional abnormality 
and 62 (70.4%) had a complex karyotype with two or more associated 
abnormalities. The most frequent additional abnormalities to chr17 were 
deletion 5q (n=38), deletion 7 or -7 (n=24), trisomy 8 (n=18), deletion 18q or -18 
(n=14), abnormalities chr3 (n=13) and abnormalities chr1 (n=10).  
There was a strong correlation between the number of chromosomal 
abnormalities found in addition to abnormalities of chr17 and particular 
characteristics of the MDS patients (Table 2).  There was a higher proportion of 
cases with monosomy 17 (p<0.001) and add17p (p=0.008) in the group with a 
complex karyotype. The i(17q) was more frequent as an isolated abnormality or 
just with one associated anomaly (p<0.001).  
No clear differences in demographic characteristics, variables used to calculate 
the IPSS, IPSS risk groups, and FAB and WHO classification were found 
between patients with loss or not loss of chr17p (17p-). 
 
Outcome and prognostic factors in the patients with abnormalities of 
chr17  
Sixty-six patients (75%) died during follow-up. Median OS was 9 months, with 
an actuarial risk of death of 47% at 6 months, 71% at 12 months, and of 78% at 
24 months. In addition, 27 patients (31%) progressed to AML during the follow-
up, with an actuarial risk of progression to AML of 19.3% at 12 months and 
20.5% at 24 months.  
The Table 3 shows the results of analyses of the different prognostic factors for 
OS and AML transformation in the patients with abnormality of chr17.  
In relation to karyotype complexity for OS and risk of AML transformation, only 
two risk groups could be clearly identified: patients with an isolated chr17 
abnormality or with one additional chromosomal abnormality and patients with 
two or more additional abnormalities (complex karyotype). Although patients 
with abnormality chr17 plus one additional abnormality had a somewhat shorter 
OS than patients with isolated abnormality chr17 the differences were not 
significant (median OS, 49 and 72 months, respectively; p=0.81). In contrast, 
patients with two or more additional abnormalities, in addition to chr17 anomaly, 
showed a much shorter OS (median OS, 5 mo) than the other two groups 
aforementioned groups (p<0.001 and p=0.004).  Regarding the risk of 
transformation to AML, the group with one additional abnormality had clearly 
lower risk than that of patients with a complex karyotype (median time to AML, 
80 months versus 12.1 months; p = 0.008).  
When analyzing the type of abnormality of chr17 we observed that cases with 
monosomy 17 had  a worse prognosis in OS and transformation to AML than 
those with i(17q)  (median OS, 6 versus 13 mo; p=0.011; median time to AML 
transformation,  10 versus 37 months; p=0.035 respectively). An isolated i(17q) 
was observed in 15 cases of the 29 cases with i(17q) (52%). The median OS for 
patients with isolated i(17q) was 29.8 months and 13.3% of them have 
transformed to AML. 
The monosomy 17 also had a worse prognosis than a complex karyotype 
without monosomy 17 with a median OS of 6 and 9.7 months, respectively 
(p=0.001).  
In the multivariate analysis we analyzed the prognostic impact concerning OS 
and AML transformation of karyotype complexity, monosomy of chr17 and 
isochromosome 17 as independent variables using the Cox regression model 
for survival data. The results showed that monosomy 17 and complex karyotype 
were independent prognostic factors for OS with a hazard ratio of 1,98 (IC95%: 
1,10-3,59; p=0,023) and 4,52 (IC95%: 2,20-9,34; p<0,001) respectively. For 
AML transformation, only complex karyotype was found as an independent 
prognostic factor with a hazard ratio of 4,59 (IC95%: 1,58-10,43; p=0,004). 
 
 
Comparison of OS and transformation to AML between patients with 
chr17 abnormality and patients with other chromosomal abnormalities not 
involving chr17 
We compared data of OS and AML transformation of 88 patients with chr17 
abnormalities with data of 1,346 patients with other chromosomal abnormalities 
not involving chr17 from the Spanish registry of MDS.  
In Figure 1 we observed that patients with abnormalities of chr17 have a worse 
prognosis than patients with an abnormal karyotype without chr17 abnormalities 
for median OS (8.7 vs 30.0 mo respectively (p <0.001)) and AML transformation 
(31% vs 22% respectively).  
We compared the prognosis of the two groups of patients in each of the IPSS 
risk groups and IPSS cytogenetic risk groups (Table 4). In the IPSS 
Intermediate-2 risk group, patients with chr17 abnormality have a worse 
prognosis (median OS of 6.6 vs 14.0 mo in those without abnormality of chr17, 
p=0.005). In the IPSS cytogenetic risk groups of 1 point, the median OS of 
patients without abnormalities chr17 is of 29.1 months versus 11.9 months in 
patients with chr17 involved (p <0.001).  
In table 5 we summarize the results restricted to the group of patients with poor 
prognosis according to IPSS. The patients with monosomy of chr17 had a 
worse prognosis and higher probability to progression to AML than patients with 
isolated monosomy of chr7 (median OS of 4.7 vs 19.0 mo, p<0.001; and 
median time to AML transformation (MTT) of 9.8 vs 36.0 mo, p=0.001, 
respectively). Also, monosomy of chr17 was associated with a worse survival 
than patients with complex karyotype without chr17 abnormalities (median OS 
of 4.7 vs 8.0 mo, p=0.015).  
In addition (Table 5), patients with i(17q), mainly with complex karyotype, have 
a worse prognosis in OS than patients with isolated monosomy of chr7 (median 
OS of 3.9 versus 19.0 mo, p=0.010). No statistical differences were found in 
survival or AML progression risk between patients with i(17q) and patients with 
complex karyotype not involving chr17.  
 
 DISCUSSION 
 
In this paper we present the results of a multicenter cooperative study that 
recruited, in our knowledge, the largest to-date series of de novo MDS patients 
with abnormalities of chromosome 17. This has allowed us to assess the clinical 
characteristics and prognostic factors, with special emphasis on cytogenetic 
findings; being the survival and the risk of transformation to AML one of the 
highlights of this study.  
According to the 1997 International Prognostic Scoring System (IPSS) (ref. 4) 
the abnormality of chr17 is grouped within the intermediate-risk cytogenetic 
group. Recently, the revised IPSS (IPSS-R) was published (ref. 25) and used 
the cytogenetic categories defined by Schanz et al (ref. 22) to stratify patients 
according five risk groups. In the proposal defined by Schanz et al., i(17)(q10) 
as a single anomaly was included in the intermediate risk category. 
 Our study aimed to characterize these patients with abnormality of chr17 and 
analyze whether we should continue to include them in the intermediate-risk 
cytogenetic group or if we need to consider chr17 alterations within groups of 
poor prognosis. This is one of the controversial points of the published studies 
about the IPSS-cytogenetic risk groups (ref. 8-12).  Herein, we have studied 
extensively the characteristics and the outcome of patients with abnormality of 
chr17 and compared them with patients with chromosome abnormalities not 
involving chr17. 
In our study, patients with abnormality of chr17 typically presented poor 
prognostic features (Table 1). 
We found that patients with abnormalities of chr17 had a worse prognosis for 
OS and AML transformation than patients with abnormal karyotype but without 
abnormalities of chr17. These results were found within the homogeneous 
intermediate-2 IPSS-risk group and 1 point IPSS cytogenetic group as well. 
When we analyzed the patients with complex karyotype, we found that if chr17 
is involved, the prognosis is worsened. 
Karyotype complexity is a well-known poor prognostic factor in MDS (ref. 4, 9, 
11, 26-28). However, in MDS patients with anomaly of chr17 the prognostic 
value of the number of chromosomal abnormalities in addition to abnormality 
chr17 (complexity of the karyotype) has not been studied to date. We found two 
different prognostic groups of patients in function of number of chromosomal 
abnormalities:  1) patients with isolated abnormality of chr17 or with one 
associated abnormality and 2) patients with two or more associated 
abnormalities (p<0.001 and p=0.004 respectively).  
The most frequent additional abnormalities to abnormality of chromosome 17 
were: del(5q), followed by del(7q), monosomy 7, trisomy 8 and del(18q)/-18, the 
incidences of which were within the ranges reported in the literature (ref. 16, 29-
34).  
Concerning the type of abnormality of chr17 we showed that the i(17q) as an 
isolated alteration have a median OS of 29.8 months, slightly higher than the 
survival described in the new proposal for cytogenetic categorization of MDS 
(ref. 22) where the 11 patients with i(17q) had an intermediate prognosis with a 
median OS of 18 mo. About 70% of i(17q) were isolated or associated with just 
one abnormality and had better prognosis in OS and transformation AML than 
patients with monosomy 17 (p = 0.011 and p = 0,035). Regarding add(17p) 
seems to be a trend to worse prognosis in OS and transformation to AML 
respect to i(17q) without reaching statistical significance (p=0.451 and p=0.852). 
This could be explained because patients with -17 or add(17p) present complex 
karyotype in the majority of cases (p<0.001 and p=0.008 respectively) and the 
i(17q) is usually as single abnormality or additional ones (p<0.001). However, at 
multivariate analysis we found that monosomy 17 is an independent prognostic 
factor. When i(17q), was included within a group of poor prognosis according 
IPSS,  had a worse prognosis than patients with isolated monosomy 7 but no 
differences with complex karyotype without chr17 involved.  
Regarding patients with monosomy of chr17, we found a worse OS and major 
risk of AML transformation than known subgroups of patients with bad 
prognosis according to IPSS (ref. 4), as -7 or complex karyotype. Several 
studies have shown in AML that the presence of autosomal chromosomal 
monosomies strongly predicted for an adverse prognosis. Negative prognostic 
impact of autosomal monosomies in AML has been described for monosomies 
of chromosomes 5 and 7 (ref. 35-37). However, according to the results, 
monosomy of chr17 should be considered as an additional worse prognosis 
factor in MDS patients and therefore, should support the possibility of a more 
upfront aggressive treatment when indicated. 
Finally, we analyzed the characteristics and outcome of 72 patients fulfilling the 
“loss chr17p” definition. Comparing the OS and risk of evolution to AML of 
patients with the “loss chr17p” vs those “without loss chr17p” no significant 
differences were observed between both groups. Our work is based on the 
results of conventional cytogenetics (karyotype), it is a retrospective study and 
LOH17, TP53 loss or TP53 mutations could not be studied. These molecular 
studies would be very interesting to confirm with prospective specimens. Also, it 
is interesting to note that i(17q) is usually presented as a single alteration and 
implies a 17q gain and 17p loss. If this were so, we might expect to find TP53 
mutated and a different phenotype and prognosis. This should be demonstrated 
analyzing mutational status of TP53 by SNP arrays or sequencing. Taking this 
into account, the group of Houston studied the mutational status of TP53 in 
AML and other myeloid disorders with i(17q) and they did not find TP53 
mutations (ref. 21) in any patient. In this regard it would be interesting to 
analyze TP53 mutational status in patients with MDS and i(17q).  
A recent revision of the cytogenetic categorization of MDS has proposed five 
prognostic subgroups (ref. 22): very good, good, intermediate, poor and very 
poor prognosis with a median OS of 60.8, 48.5, 24, 14 and 5.7 months 
respectively. If we extrapolate the median survival of our patients with respect to 
that described by the IPSS-R (ref. 25), we may conclude that: the alterations of 
chr17 should be considered within group of poor prognosis (median OS 9 mo); 
i(17q) as an isolated disorder or with one additional alteration, may be included 
within the intermediate risk group (median OS  29.8); monosomy 17 has a much 
worse prognosis and we believe that these alterations should be included within 
the very poor prognosis group (median OS  6.2 mo). The rest of alterations of 
chr17 which include complex karyotype without monosomy 17 could be 
included into the poor prognosis group (median OS of 9.7 mo). 
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Table 1 Characteristics of the patients with abnormality of chr17  
Characteristic Number of patients, n (%) 
Total number of patients 88 
Age 
< 60 years 
≥ 60 years 
88 
9 (10.2) 
79 (89.8) 
Sex 
Male 
Female 
88 
57 (64.8) 
31 (35.2) 
Hemoglobin 
< 10 g gr/dL 
≥ 10 g gr/dL 
87 
 63 (72.4) 
24 (27.6) 
Absolute neutrophil count 
< 1.8 x 10
9
 per liter 
≥ 1.8 x 10
9
 per liter 
85 
56 (65.9) 
29 (34.1) 
Platelet count 
< 100 x 10
9
 per liter 
≥ 100 x 10
9
 per liter 
87 
51 (58.6) 
36 (41.4) 
Cytopenias 
0-1 
2-3 
86 
23 (26.7) 
63 (73.3) 
BM blast count 
< 5% 
5-10% 
11-19% 
88 
28 (31.8) 
24 (27.3) 
36 (40.9) 
FAB subtype 
RA 
RARS 
RAEB 
88 
21 (23.9) 
6 (6.8) 
61 (69.3) 
WHO subtype* 
RA 
RARS 
RCMD 
RCMD-RS 
RAEB-1 
RAEB-2 
84*  
3 (3.6) 
3 (3.6) 
13 (15.5) 
4 (4.7) 
24 (28.6) 
37 (44.0) 
Karyotype complexity 
Isolated abnormality chr17 
Abnormality chr17 + 1 abnormality 
Abnormality chr17 + 2 abnormality 
Abnormality chr17 + 3 abnormality 
Abnormality chr17 + ≥ 4 abnormality 
88 
18 (20.5) 
8 (9.1) 
5 (5.7) 
9 (10.2) 
48 (54.5) 
Loss cr17p 
Yes 
Non 
88 
72 (81.8) 
16 (18.2) 
Chr17 type of anomaly 
i (17q) 
-17 
add(17p) 
+ 17 
t 17 
others 
-17 and add(17p) 
-17 and i(17q) 
-17 and t 17 
t17 and others 
88 
29 (33.0) 
26 (29.5) 
13 (14.8) 
5 (5.7) 
3 (3.4) 
5 (5.7) 
1 (1.1) 
1 (1.1) 
2 (2.3) 
3 (3.4) 
IPSS risk group 
Low 
Intermediate-1 
Intermediate-2 
High 
86 
0 (0) 
19 (22.1) 
35 (40.7) 
32 (37.2) 
 
Table 1
Table 1: Characteristics of the patients with abnormality of chr17  
Abbreviations: BM, bone marrow; FAB, French-American-British; IPSS, 
International Prognostic Scoring System; RA, refractory anemia; RAEB, RA with 
excess of blasts; RARS, RA with ringed sideroblasts; RCDM, refractory 
cytopenia with multilineage dysplasia; RCMD-RS, RCMD with ringed 
sideroblasts; WHO, World Health Organization; i(17q), isochromosome 17q; -
17, monosomy chr17; add(17p), additional 17p; +17, trisomy cr17; t17, 
translocation chr17.  
*In 4 patients WHO classification was not possible due to insufficient data. 
 
 
Table 1 Legend
 
Table 2 Patient characteristics according to the karyotype complexity. 
 isolated 
abnormality chr17 and  
abnormality chr17 + 1 abnormality  
abnormality chr17 + ≥ 2 
abnormalities  
p value 
 Median  
(Q1-Q3) 
N (%) Median (Q1-Q3) N (%)  
Age 
< 60 years 
≥ 60 years 
72.98 
(65-78.9) 
26 
3 (33.3) 
23 (29.1) 
73.34 
(64.09-79.69) 
62 
6 (66.7) 
56 (70.9) 
0.793 
Sex 
Male 
Female 
 
26 
21 (36.8) 
5 (16.1) 
 
62 
36 (63.2) 
26 (83.9) 
0.042 
Hemoglobin 
< 10 g gr/dL 
≥ 10 g gr/dL 
9.3 
(8.4-10.4) 
26 
16 (25.4) 
10 (41.7) 
8.9 
(7.8-9.8) 
61 
47 (74.6) 
14 (58.3) 
0.138 
Absolute neutrophil count 
< 1.8 x 10
9
 per liter 
≥ 1.8 x 10
9
 per liter 
1.68 
(0.8-2.37) 
25 
14 (25.0) 
11 (37.9) 
1.09 
(0.61-2.33) 
60 
42 (75.0) 
18 (62.1) 
0.215 
Platelet count 
< 100 x 10
9
 per liter 
≥ 100 x 10
9
 per liter 
113.5 
(40-187) 
26 
12 (23.5) 
14 (38.9) 
60 
(36-124) 
61 
39 (76.5) 
22 (61.1) 
0.123 
Cytopenias 
0-1 
2-3 
 
25 
9 (39.1) 
16 (25.4) 
 
61 
14 (60.9) 
47 (74.6) 
0.214 
BM blast count 
< 5% 
5-10% 
11-19% 
5.0 
(3.0-10.0) 
26 
11 (39.3) 
8 (33.3) 
7 (19.4) 
9.0 
(4.0-14.0) 
62 
17 (60.7) 
16 (66.7) 
29 (80.6) 
0.201 
FAB subtype 
RA 
RARS 
RAEB 
 
26 
8 (38.1) 
4 (66.7) 
14 (23.0) 
 62 
13 (61.9) 
2 (33.3) 
47 (77.0) 
0.050 
WHO subtype * 
RA + RARS 
RCMD + RCMD-RS 
RAEB-1 
RAEB-2 
 25 
2 (33.3) 
9 (52.9) 
7 (29.2) 
7 (18.9) 
 59 
4 (66.7) 
8 (47.1) 
17 (70.8) 
30 (81.1) 
0.090 
IPSS risk group 
Intermediate-1 
Intermediate-2 
High 
 26 
15 (78.9) 
7 (20.0) 
4 (12.5) 
 60 
4 (21.1) 
28 (80.0) 
28 (87.5) 
<0.001 
Loss chr17p 
Yes 
Non 
 26 
21 (29.2) 
5 (31.2) 
 62 
51 (70.8) 
11 (68.8) 
0.869 
Chr17 type of abnormality** 
i (17q) 
-17 
add(17p) 
trisomy 17 
traslocation 17 
 24 
20 (69.0) 
1 (3.8) 
0 (0) 
3 (60.0) 
0 (0) 
 52 
9 (31.0) 
25 (96.2) 
13 (100) 
2 (40.0) 
3 (100) 
<0.001 
<0.001 
<0.001 
0.008 
0.124 
0.055 
 
Table 2
Table 2: Patient characteristics according to the karyotype complexity. 
 
Abbreviations: BM, bone marrow; FAB, French-American-British; IPSS, 
International Prognostic Scoring System; RA, refractory anemia; RAEB, RA 
with excess of blasts; RARS, RA with ringed sideroblasts; RCDM, refractory 
cytopenia with multilineage dysplasia; RCMD-RS, RCMD with ringed 
sideroblasts; WHO, World Health Organization. Q1, percentile 25; Q3, 
percentile 75. 
* In 4 patients WHO classification was not possible due to insufficient data. 
** Other abnormalities and associations of two abnormalities of chr17 not 
shown. Each subtype is compared with the presence or absence the 
abnormality between the group of karyotype complexity. 
 
Table 2 Legend
Table 3 Results of analyses of prognostic factors for OS and AML transformation in the patients 
with abnormality of chr17 
 Overall survival AML transformation 
 N (%) Median 
survival 
(mo) 
Patients 
alive at 1 
year (%) 
p value N (%) Median AML 
transformation 
(mo) 
Patients 
transforme
d in AML 
(%) 
p value 
Age 
< 60 years 
≥ 60 years 
88 (100) 
9 (10.2) 
79 (89.8) 
 
12.2 
8.1 
 
44.4 
27.8 
0.053 27 (30.6) 
4 (14.8) 
23 (85.2) 
 
36.5 
29.4 
 
44.4 
29.1 
0.652 
Sex 
Male 
Female 
88 (100) 
57 (64.8) 
31 (35.2) 
 
9.1 
6.2 
 
28.1 
32.3 
0.474 27 (100) 
15 (55.5) 
12 (44.5) 
 
33.1 
27.0 
 
26.3 
38.7 
0.301 
Hemoglobin 
< 10 gr/dL 
≥ 10 gr/dL 
87 (98.8) 
63 (71.6) 
24 (27.3) 
 
7.3 
12.2 
 
25.4 
41.7 
0.121 27 (100) 
15 (55.5) 
12 (44.5) 
 
34.6 
29.4 
 
23.8 
50.0 
0.465 
Absolute neutrophil count 
< 1.8 x 10
9
 per liter 
≥ 1.8 x 10
9
 per liter 
85 (96.5) 
56 (63.6) 
29 (33.0) 
 
9.0 
8.5 
 
25.0 
37.9 
0.919 27 (100) 
17 (62.9) 
10 (37.1) 
 
32.0 
33.1 
 
30.4 
34.5 
0.812 
Platelet count 
< 100 x 10
9
 per liter 
≥ 100 x 10
9
 per liter 
87 (98.8) 
51 (58) 
36 (40.9) 
 
7.5 
27.1 
 
21.6 
41.7 
0.007 27 (100) 
15 (55.5) 
12 (44.5) 
 
27.0 
36.5 
 
29.4 
33.3 
0.129 
Cytopenias 
0-1 
2-3 
86 (97.7) 
23 (26.7) 
63(73.3) 
 
20.9 
7.5 
 
47.8 
22.2 
0.068 27 (100) 
11 (40.7) 
16 (59.3) 
 
33.1 
32.0 
 
47.8 
25.4 
0.809 
BM blast count 
< 5% (1) 
5-10% (2) 
11-19% (3) 
88 (100) 
28 (31.8) 
24 (27.3) 
36 (40.9) 
 
12.2 
6.8 
7.3 
 
39.3 
16.7 
30.6 
0.205 
(1) vs (2) 0.046 
(1)vs(3) 0.201 
(2) vs (3) 0.628 
27 (100) 
7 (25.9) 
6 (22.2) 
14 (51.9) 
 
34.6 
12.1 
27.4 
 
25 
25 
38.9 
0.168 
(1)vs(2)0.094 
(1)vs(3)0.075 
(2)vs(3)0.921 
FAB subtype 
RA + RARS 
RAEB 
88 (100) 
27 (30.7) 
61 (69.3) 
 
12.2 
7.3 
 
44.4 
23.0 
0.110 27 (100) 
7 (25.9) 
20 (74.1) 
 
34.6 
27.0 
 
25.9 
32.8 
0.063 
WHO subtype 
RA + RARS (1) 
RCMD + RCMD-RS (2) 
RAEB-1 (3) 
RAEB-2 (4) 
84 (95.4) 
6 (7.6) 
17 (21.7) 
24 (27.2) 
37 (41.3) 
 
36 
12.0 
6.8 
7.3 
 
83.3 
35.3 
16.7 
27.9 
0.312 
(1)vs(2) 0.210 
(1)vs(3) 0.022 
(1)vs(4) 0.125 
(2)vs(3) 0.280 
(2)vs(4) 0.501 
(3)vs(4) 0.815 
27 (100) 
2 (7.5) 
5 (18.5) 
5 (18.5) 
15 (55.5) 
 
79.9 
32.0 
---* 
27.0 
 
33.3 
29.4 
20.8 
40.5 
0.232 
(1)vs(2) 0.051 
(1)vs(3) 0.141 
(1)vs(4) 0.049 
(2)vs(3) 0.630 
(2)vs(4) 0.575 
(3)vs(4) 0.575 
 
IPSS risk group 
Intermediate-1 (1) 
Intermediate-2 (2) 
High (3) 
86 (97.7) 
19 (21.6) 
35 (39.8) 
32 (36.4) 
 
36 
6.6 
6.2 
 
 
62.2 
17.1 
25.0 
0.025 
(1) vs (2) 0.007 
(1) vs (3) 0.007 
(2) vs (3) 0.955 
27 (100) 
6 (22.2) 
8 (29.6) 
13 (48.2) 
 
79.9 
29.4 
10.0 
 
31.6 
22.9 
40.6 
0.050 
(1) vs (2) 0.090 
(1) vs (3) 0.008 
(2) vs (3) 0.576 
karyotype complexity 
    Isolated abnormality chr17 (1) 
    Alt. chr17 + 1 abnormality (2) 
    Abnormality chr17 + ≥ 2 
abnormalities (3) 
88 (100) 
18 (20.4) 
8 (9.0) 
62 (70.5) 
 
71.8 
48.7 
5.4 
 
61.1 
55.6 
16.4 
<0.001 
(1) vs (2) 0.808 
(1) vs (3) <0.001 
(2) vs (3)  0.004 
27 (100) 
4 (14.8) 
3 (11.1) 
20 (74.1) 
 
---* 
79.9 
12.1 
 
22.2 
37.5 
32.3 
0.008 
(1) vs (2) 0.739 
(1) vs (3) 0.007 
(2) vs (3)  0.068 
Type of abnormality chr17 
   i(17q) (1) 
   -17 (2) 
   add(17p) (3) 
 
 
76 (86.3) 
29 (33.0) 
26 (29.5) 
13 (14.8) 
 
 
13.4 
6.2 
12.0 
 
 
48.3 
11.5 
30.8 
 
0.018 
(1) vs (2) 0.011 
(1) vs (3) 0.451 
(2) vs (3) 0.206 
27 (100) 
8 (29.6) 
11 (40.7) 
4 (14.8) 
 
36.8 
9.8 
34.9 
 
27.6 
42.3 
30.8 
0.125 
(1) vs (2) 0.035 
(1) vs (3) 0.852 
(2) vs (3) 0.056 
 
Loss cr17p 
Yes 
Non 
88 (100) 
72 (81.8) 
16(18.2) 
 
8.1 
9.7 
 
39.2 
31.3 
0.233 27 (100) 
23 (85.2) 
4 (14.8) 
 
29.4 
79.9 
 
31.9 
25 
0.291 
 
 
Table 3
Table 3: Results of analyses of prognostic factors for OS and AML 
transformation in the patients with abnormality of chr17 
 
Abbreviations: AML, acute myeloid leukemia; BM, bone marrow; FAB, French-
American-British; IPSS, International Prognostic Scoring System; RA, refractory 
anemia; RAEB, RA with excess of blasts; RARS, RA with ringed sideroblasts; RCDM, 
refractory cytopenia with multilineage dysplasia; RCMD-RS, RCMD with ringed 
sideroblasts; WHO, World Health Organization. 
* median not reached 
Table 3 Legend
Table 4 Results OS between patients with abnormality of chr17 vs without 
abnormality of  chr17 for each IPSS risk-group.  
 
  Overall survival 
  Abnormality of 
chr17 
No abnormality of 
chr17* 
p value 
  N MST N MST  
IPSS risk group 
Intermediate-1 19 36.3 508 42.0 0.134 
Intermediate-2 35 6.7 300 14.0 0.005 
High risk 32 6.3 227 8 0.644 
IPSS cytogenetic 
group 
0.5 25 60.3 526 54.3 0.229 
1 63 11.9 358 29.1 <0.001 
 
Table 4
Table 4: Results OS between patients with abnormality of chr17 vs without 
abnormality of chr17 for each IPSS risk-group.  
 
* Patients with a low IPSS risk group and 0 points of the IPSS cytogenetic group 
not shown. 
MST (Median OS);  
 
Table 4 Legend
Table 5 OS and AML transformation in high risk-group of IPSS according 
to type of alteration of crh17.  
 
  Overall survival AML transformation  
 N MST 
(mo) 
Exitus 
(%) 
p value MTT 
(mo) 
Patients 
transformed in 
AML (%) 
p value 
Monosomy of cr17 (1) 
Isochromosome of cr17 (2) 
Monosomy of cr7 (3) 
Complex karyotype* (4) 
25 
10 
56 
234 
4.7 
3.9 
19.0 
8.0 
88.0 
100.0 
64.3 
79.5 
(1) vs (3) <0.001 
(1) vs (4) 0.015 
(2) vs (3) 0.010 
(2) vs (4) 0.183 
9.8 
---** 
36.0 
16.0 
40.0 
40.0 
26.8  
34.2 
(1) vs (3) 0.001 
(1) vs (4) 0.084 
(2) vs (3) 0.110 
(2) vs (4) 0.310 
 
Table 5
Table 5: OS and AML transformation in high risk-group of IPSS according 
to type of alteration of crh17. 
 
* Patients with complex karyotype involving abnormalities of chr7 and chr17 not 
included 
** MTT not reached 
MST (Median OS); MTT (median time to AML transformation) 
 
Table 5 Legend
Figure 1: Compared data of OS and LAM transformation of patients with chr17 
abnormalities with patients with other chromosomal abnormalities not involving chr17. 
Figure 1A 
 
Figure 1B 
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